SOURCE: Flamel Technologies

Flamel Technologies

March 05, 2015 16:01 ET

Flamel Technologies to Present at Two Upcoming Investor Conferences

LYON, FRANCE--(Marketwired - Mar 5, 2015) - Flamel Technologies S.A. (NASDAQ: FLML) today announced that the Company will be presenting at two upcoming investor conferences. 

Steve Lisi, the Company's Senior Vice President of Business and Corporate Development, will be presenting at the 27th Annual ROTH Conference to be held March 9 - 12, 2015 at the Ritz Carlton in Laguna Niguel, California. Flamel's presentation is scheduled for Tuesday, March 10th, at 10:00 AM Pacific Time.

Michael Anderson, Chief Executive Officer, along with Mr. Lisi will be presenting at the Barclays Global Healthcare Conference to be held March 10 - 12, 2015 at the Loews Miami Beach Hotel, Florida. Flamel's presentation is scheduled for Thursday, March 12th, at 8:00 AM Eastern Time.

Both presentations will be available for review on the Investor Relations section of the Company's website at

About Flamel Technologies -- Flamel Technologies SA's (NASDAQ: FLML) business model is to blend high-value internally developed products with its leading drug delivery capabilities. The Company markets Bloxiverz™ (neostigmine methylsulfate) and Vazculep™ (phenylephrine hydrochloride) in the US and licenses the Micropump-based microparticles technology to Recipharm AB for application to the manufacturing under FDA-audited GMP guidelines of Coreg CR® (carvedilol phosphate), marketed in the USA by GlaxoSmithKline. The Company has a proprietary pipeline of niche specialty pharmaceutical products, while its drug delivery platforms are focused on the goal of developing safer, more efficacious formulations of drugs to address unmet medical needs. Its pipeline includes chemical and biological drugs formulated with its Micropump® (and its applications to the development of liquid formulations LiquiTime® and of abuse-deterrent formulations Trigger Lock™) and Medusa™ proprietary drug delivery platforms. Several Medusa-based products have been successfully tested in clinical trials. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and Dublin, Ireland. Additional information may be found at